A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials

I Kitty Stanley; Anton M Palma; Andrea K Viecelli; David W Johnson; Carmel M Hawley; Christine E Staatz; Andrew J Mallett

doi:10.1007/s40620-024-01906-x

A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials

J Nephrol. 2024 Mar 21. doi: 10.1007/s40620-024-01906-x. Online ahead of print.

Authors

I Kitty Stanley¹, Anton M Palma², Andrea K Viecelli^{3

4

5}, David W Johnson^{3

4

5}, Carmel M Hawley^{3

4

5}, Christine E Staatz⁶, Andrew J Mallett^{7

8

9

10}

Affiliations

¹ Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia. i.stanley@uq.edu.au.
² Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
³ Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia.
⁴ Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Australia.
⁵ Centre for Kidney Disease Research, The University of Queensland, Brisbane, Australia.
⁶ School of Pharmacy, The University of Queensland, Brisbane, Australia.
⁷ Centre for Kidney Disease Research, The University of Queensland, Brisbane, Australia. andrew.mallett@health.qld.gov.au.
⁸ Department of Renal Medicine, Townsville University Hospital, Townsville, Australia. andrew.mallett@health.qld.gov.au.
⁹ College of Medicine and Dentistry, James Cook University, Townsville, Australia. andrew.mallett@health.qld.gov.au.
¹⁰ Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia. andrew.mallett@health.qld.gov.au.

PMID: 38512373
DOI: 10.1007/s40620-024-01906-x

No abstract available

Publication types

Letter